All In MedTech

Device Trial Radar · NCT06824987

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants With APOL1-Mediated Kidney Disease (APPRECIATE)

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

63

Actual

Start

Mar 5, 2025

Primary completion

Oct 4, 2027

Study completion Oct 4, 2027

Sponsor

Lead sponsor
AstraZenecaNot on our public-company list
Sponsor type
Industry
First posted
Feb 13, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.

Conditions

  • APOL1-Mediated Kidney Disease

Interventions

  • AZD2373-Arm 1Combination product

    Accessorized Pre-Filled Syringe (Solution for injection)

  • AZD2373-Arm 2Combination product

    Accessorized Pre-Filled Syringe (Solution for injection)

  • PlaceboCombination product

    Accessorized Pre-Filled Syringe (Solution for injection).

  • APOL1 Genotyping Clinical Trial AssayDevice

    The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in Urine Albumin-Creatinine Ratio (UACR)Time frame: From Baseline at Week 30

Locations

96 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Alabaster, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Irondale, Alabama

93 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.